Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent
Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.
You may also be interested in...
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.